Argenx
ARGX
#432
Rank
NZ$102.10 B
Marketcap
NZ$1,634
Share price
1.68%
Change (1 day)
80.58%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$27.84. In 2025 the company made an earnings per share (EPS) of NZ$37.12 an increase over its 2024 EPS that were of NZ$24.51.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23-26.65%
2025NZ$37.1251.44%
2024NZ$24.51-369.77%
2023NZ-$9.09-60.46%
2022NZ-$22.9863.33%
2021NZ-$14.07-40.37%
2020NZ-$23.60183.47%
2019NZ-$8.32123.09%
2018NZ-$3.7354.93%
2017NZ-$2.4114.07%
2016NZ-$2.1113.05%
2015NZ-$1.87-36.34%
2014NZ-$2.93209.04%
2013NZ-$0.95-33.99%
2012NZ-$1.44185.59%
2011NZ-$0.50